Nervgen Pharma Corp NGEN

$1.62 +0.06 (3.51%)

Valuation

Market cap
126,188,000
Revenue TTM
$0
Net income TTM
$-31,570,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
475,200
Avg volume
531,204
Day's range
$1.55 – $1.66
Shares out
80,631,000
Stochastic %K
21%
Beta
—
Analysts
Strong Sell
Price target
$10.33

Price

Company profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300...

Show more

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
778 731 1711
Website
https://nervgen.com
Address
112-970 Burrard Street, Unit 1290, Vancouver, Canada

Latest news

Stocktwits

DavesStockPicks Oct 16, 5:16 AM
$NGEN A mini short squeeze would be hilarious. A good way to kick off a run.
0 replies
BenUnknown Oct 16, 2:53 AM 0 replies
Floridaorange Oct 15, 9:39 PM
$NGEN Decades of research & 2009 molecular discovery & 2015 functional recovery in animals & 2018 independent Cologne replication & 2023 chronic fine-motor recovery evidence & 2025–2026 encouraging human clinical findings & RESTORE Phase 3.
0 replies
Floridaorange Oct 15, 9:29 PM
$NGEN “The functional results are encouraging, but less definitive." Actually the functional improvements weren't isolated. They accompanied significant hand-MEP findings and other physiological observations, along with supportive exploratory biomechanical and patient-reported outcomes. RESTORE was designed to address CONNECT's weaknesses This is where your assessment is most incomplete. RESTORE isn't simply repeating CONNECT with more patients. It includes: A functional primary endpoint based on the encouraging CONNECT hand-function results. An FDA-aligned registrational design. A larger, more statistically robust population. A power calculation allowing a smaller treatment effect than CONNECT's observed difference. Standardised assessments intended to reduce measurement variability.
1 replies
aladdinscarpet Oct 15, 8:17 PM
$NGEN Not until after BO; plenty of time…
2 replies
KvoGicho Oct 15, 8:15 PM 0 replies
BeefStewart Oct 15, 7:31 PM
$NGEN I have no position here at the time of this post, but I find it very interesting nevertheless. I missed the last run from the 1.60s or so to about 2.30ish.. I wonder if we'll see a similar increase again... Best of luck everyone.
1 replies
BeefStewart Oct 15, 7:25 PM 0 replies